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Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in
cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult
to treat with conventional therapy due to dose-limiting toxicities. With the recent success
of CD 19 CAR in pediatric patients with B cell acute lymphoblastic leukemia (ALL), this
mode of therapy has become a very attractive option for these patients with high-risk
disease. In this review, we will discuss current treatment paradigms of pediatric acute
leukemia and potential therapeutic targets for additional high-risk populations, including
T cell ALL, AML, and infant ALL.
Keywords: chimeric antigen receptor, immunotherapy, adoptive, relapsed leukemia, chimeric antigen receptor
safety, pediatric acute leukemia

Introduction
From 1975 to 2010, the overall incidence of pediatric cancer in the US has increased slightly, by an
average of 0.6% per year (1). Acute lymphoblastic leukemia (ALL) remains the most commonly
diagnosed malignancy in pediatrics, with approximately 2,900 new cases/year in the United States
(1). With intensive multi-drug chemotherapy children with standard risk (SR) B-precursor ALL, as
defined by the NCI/Rome criteria (age 1–9.99 years and initial white blood count <50,000/μL), have
cure rates of ~90% (2). However due to its high incidence, acute leukemia remains the leading cause
of death in pediatric patients with cancer. Recent clinical trials have risk-stratified patients based on
cytogenetics, clinical variables [central nervous system (CNS) and testicular status], and early treatment response (3). Children’s Oncology Group (COG) retrospectively reviewed more than 6,000
pediatric patients with newly diagnosed ALL and adopted a four-group classification after induction
therapy: low-risk, average-risk, high-risk, and very high-risk (4). The 4-year event-free survival
(EFS) varied intensely among the four groups, 91, 86, 76, and 46%, respectively, demonstrating the
need to identify high-risk patients earlier, and alter therapy accordingly, including the incorporation
of novel treatment approaches for those patients in the highest risk categories (5). This risk-adapted
classification aims to give patients the best chance at cure while sparing unnecessary toxicity.
The reality of relapse and/or refractory disease has been a challenge for oncologists as toxicity
of conventional therapy has limited dose escalation, and EFS for these high-risk patients remains
suboptimal. Relapse of ALL is defined as disease recurrence at any site after a period of time in which
the disease was in complete remission. Refractory disease is defined as inability to achieve a complete
remission despite multiple induction attempts. After relapse, chance of cure significantly diminishes

1

October 2015 | Volume 3 | Article 80

Shalabi et al.

Alternative immunotherapy targets in pediatric leukemia

due to acquired mechanism of resistance and poor treatment
tolerance. With first line chemotherapy intensified to induce a
remission, leukemic blasts that are present at relapse have been
exposed to the most effective drug regimens and have gained
mechanisms that help them survive these cytotoxic agents (6).
With a combination of chemotherapy and hematopoietic stem cell
transplant (HSCT), 30–50% of all children with relapsed ALL can
be cured albeit with the potential for substantial morbidity (7, 8).
Results from the Children’s Cancer Group (CCG) 1941 marrow
relapse study showed that 50% of patients failed to enter remission, died from toxicity, or relapsed again after achieving a brief
second remission (9). Prognostic factors associated with relapse
leading to poor outcome include time to relapse, site of relapse,
cytogenetics, and immunophenotype [T cell ALL, infant ALL,
acute myeloid leukemia (AML)] (6, 10). This review will focus
on acute leukemia in pediatrics and discuss current treatment
paradigms and potential therapeutic targets for immunotherapy.

late relapse (CR1 ≥36 months) (15). Collectively, these results
demonstrate that early and isolated medullary relapse are poor
prognostic indicators for patients.
Historically, patients diagnosed with Philadelphia chromosome-positive (Ph+) ALL (BCR–ABL fusion) have had poor outcomes. However, with the discovery of tyrosine kinase inhibitors
(TKI), this high-risk subgroup has transformed into a leukemia
that is curable. In childhood Ph+ ALL, imatinib mesylate, one of
the first TKI, has shown tremendous improvements in 5-year EFS
when combined with chemotherapy, 70 ± 6 vs. historical controls
with chemotherapy 35 ± 4% (16). Genetic studies over the last
decade have identified a Ph-like subtype of leukemia that also has
dismal outcomes in pediatric patients with ALL. This group does
not have the typical BCR–ABL fusion protein, but shares a similar
gene-expression profile to Ph+ ALL (17). It is characterized by
deletions in genes that are involved in B cell development and
signaling pathways, IKAROS, PAX5, E2A, among others, and has
shown resistance to standard chemotherapy (18). In a retrospective review of 1,700 previously diagnosed patients with pre-B cell
ALL, 15% of these patients were identified as having Ph-like ALL
based on genetic studies. Comparative analysis showed that the
5-year EFS and OS among patients with Ph-like ALL were inferior
to children with other HR B cell ALL, 58.2 ± 5.3 vs. 83.9 ± 1.5%
and 72.8 ± 4.8 vs. 92.1 ± 1.1%, P < 0.001, respectively (17).
This trend was also noted in adolescent and young adult patient
populations. Further studies in this subpopulation are needed
to determine if small molecule inhibitors in combination with
standard chemotherapy can improve remission rates.
Another significant prognostic indicator in children with pre-B
ALL is blast cell ploidy. Hypoploidy is defined as a karyotype that
has fewer than 45 chromosomes, and has been associated with
poor prognosis in pediatric patients with ALL. Approximately
6% of newly diagnosed B cell ALL patients have hypoploidy,
which is comprised of high-hypodiploid (45 chromosomes), lowhypodiploid (36–44 chromosomes), and near-haploid (25–29
chromosomes) (19). Most patients in this category have blast cells
with 45 chromosomes, with approximately 1% of patients having
fewer than 44 chromosomes. In a retrospective review performed
at St. Jude Children’s Research Hospital, 979 newly diagnosed
patients with ALL underwent a complete chromosomal analysis
and 6.8% of patients were identified as having hypoploidy (19).
Results of this study showed that patients with high-hypodiploid
had outcomes similar to SR patients; however, patients with blast
cells <45 chromosomes had significantly inferior 5-year EFS,
74.9 ± 1.6 vs. 20 ± 10.3%, p < 0.001, respectively (19). In another
retrospective collaborative review, 130 cases of low-hypodiploid
(<44 chromosomes) were analyzed and results were similar to
the St. Jude experience, showing that patients with more than 44
chromosomes had better EFS and OS than those with <44 chromosomes (5-year EFS 52.2 ± 9.3 vs. 30.1 ± 7.0%, P = 0.01) (20). A
recent paper by Mehta et al. described 78 pediatric patients with
hypodiploid ALL who underwent a myeloablative HSCT from
1990 to 2010 and showed that those children with fewer than
43 chromosomes had higher mortality and treatment-related
failures. The 5-year OS for patients with ≤43 chromosomes
adjusted for disease status and transplant time period was 38 vs.
71% for those with ≥44 chromosomes, p = 0.01 (21). Thus, more

Acute Leukemia Subtypes in Pediatrics
B Cell Leukemia

Although the majority of patients diagnosed with pre-B cell ALL
are cured, patients with certain prognostic indicators known thus
far, such as early relapse, unfavorable cytogenetics, hypodiploidy,
persistent minimal residual disease (MRD), have more challenges
achieving and sustaining a remission. Pediatric Oncology Group
(POG) 9061 aimed at treating patients with isolated CNS relapse
with intensive chemotherapy and delayed radiation therapy
(RT). The study showed improved outcomes with a delay in RT
by 6 months, so more intense systemic chemotherapy could be
administered. The 4-year EFS for patients with a complete first
remission (CR1) ≥18 months was 84 ± 5% compared to 46 ± 10%
for those with CR1 <18 months (p = 0.0002) (11). In support
of these data, the results of POG 9412 also demonstrated better
outcome for those patients with isolated CNS relapse with CR1
≥18 months with a 3-year EFS of 77 ± 7% compared to 52 ± 11%
EFS for those with CR1 <18 months (p = 0.0267) (12). Historically,
patients with bone marrow relapse, early and late, have had challenges entering a CR2 and have had poor overall outcomes. COG
study AALL01P2 looked at inducing a CR2 in patients with early
(<36 months from initial CR) or late (>36 months from initial
CR) medullary relapse with higher intensity induction chemotherapy. The 4-month EFS for early and late isolated B-precursor
marrow relapse were 62 ± 6% (n = 72) and 93 ± 4% (n = 55),
respectively (13). These results are comparable to previous CCG
and St. Jude studies. Analysis of relapsed HR-ALL patients treated
with either standard or augmented post induction therapy on
CCG 1961 demonstrated that 3-year post-relapse survival
(PRS) was 30 ± 3.7% (CR1 <36 months) vs. 57.8 ± 6.4% (CR1
≥36 months), P < 0.0001 (14). Also it showed that patients with
isolated CNS relapse had better PRS than those with medullary
relapse, 52.2 ± 7.4 and 29.7 ± 3.7%, respectively (P < 0.001)
(14). Similarly, St. Jude evaluated 106 patients with isolated or
combined marrow relapse disease and saw a second remission
in 66% of early relapse patients vs. 81% of late relapse patients.
The 5-year EFS estimates for patients with early relapse (CR1
<36 months) were 12.5 ± 3.9 vs. 42.6 ± 7.8% for patients with
Frontiers in Pediatrics | www.frontiersin.org
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therapeutic studies are needed for this patient population in order
to achieve higher remission rates.
Minimal residual disease has been shown to be an important
prognostic marker in patients with ALL. A prospective study by
Coustan-Smith et al. looked at MRD in 195 newly diagnosed
pediatric patients with ALL who received induction therapy.
MRD positivity was defined as those patients who had ≥0.01%
of leukemia blasts identified by flow cytometry. This study noted
a significant difference in the 5-year cumulative incidence of
relapse of patients who had MRD-positive disease as compared to
those children who were MRD-negative after induction therapy,
43 ± 21 vs. 10 ± 3%, P < 0.001 (22). Additionally, a prospective
study performed by COG assessed 1971 pediatric patients after
induction therapy. Patients who had MRD ≥0.01% had a 5-year
EFS of 59 ± 5%, as compared to those who were MRD-negative
at the end of induction, 88 ± 1%, P < 0.0001 (23). Intensification
of therapy is currently the standard of care for those patients
with ALL that have day-29 MRD ≥0.01%. In one recent study,
Borowitz et al. showed that intensifying chemotherapy based
on MRD positivity after induction can improve EFS transiently;
however, OS and 3-year EFS did not differ (24). Continued trials
are ongoing to determine if this upstaging improves outcomes for
this patient population.
In multiple retrospective reviews, MRD appeared to contribute
significantly to outcomes in pediatric patients after HSCT. In one
prospective study, 25 patients had MRD testing prior to HSCT,
with 17 of these patients having MRD-negative disease. Six out
of eight patients with MRD-positive disease relapsed post HSCT
as compared to one in the MRD-negative cohort, P < 0.0001 (25,
26). Additionally, in a recent study performed by COG and the
Pediatric Blood and Marrow Transplant Consortium (PBMTC),
144 patients with HR-ALL underwent HSCT and results of this
study demonstrated that patients who entered transplant with
MRD ≥0.1% disease had a higher risk of relapse after transplant,
HR 3.3, P = 0.01 (27). The importance of MRD prior to transplant
has been emphasized in a recent publication from this study
where next generation sequencing of the immunoglobulin V(D)
J region was used to identify MRD at very low levels, with no
relapses occurring in the group that was MRD-negative using this
ultra-sensitive method (28). Although the use of conventional
chemotherapeutic agents remains the mainstay of treatment for
pediatric patients with acute leukemia, those patients with persistent MRD-positivity represent an extremely high-risk group
that may benefit from novel therapeutic approaches in order to
eliminate their leukemia burden (26).
Several trials have been performed in order to determine what
the best treatment course for patients with high-risk acute leukemia should be and results are inconclusive. In a study performed
by Leung et al., patients with HR-ALL and AML had favorable
outcomes after HSCT (29). Transplant is thought to be more
effective than chemotherapy alone due to at least two different
factors: myeloablative conditioning and graft vs. leukemia (GVL)
effect. The use of total body irradiation as part of the myeloablative
conditioning is generally used in patients with ALL to facilitate
better engraftment and to more effectively eliminate any leukemia
cells that remain prior to transplant (30, 31), however, whether
this TBI-based conditioning is more effective than chemotherapy
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only preparative regimens has not been proven in randomized
trials. Nonetheless, the American Society for Blood and Marrow
Transplantation (ASBMT) recommends myeloablative TBI
regimens for all patients with ALL undergoing HSCT based on
non-randomized data suggesting better survival outcomes (32).
GVL effect has been confirmed as a contributor to the curative
potential of allogeneic HSCT for leukemia mediated primarily
by donor lymphocytes (T cells and natural killer cells) that can
control MRD and maintain remission. Although the potency of
GVL for ALL has been challenged, in the above-mentioned COG
and PBMTC trial, ASCT0431, patients were randomly assigned
to standard GVHD treatment arm, tacrolimus/methotrexate,
vs. the experimental arm, sirolimus/tacrolimus/methotrexate.
The addition of sirolimus did decrease Grades 2–4 acute GVHD
significantly in patients but did not improve patient survival. It
was noted that those patients who developed Grade 1–3 acute
GVHD had an improved EFS, HR 0.5, P = 0.02, suggesting that
the GVL effect can confer a survival advantage in ALL (27).
In a prospective study of children diagnosed with very highrisk ALL, as defined by refractory disease, t(9;22) or t(4;11) clonal
abnormalities, and prednisone-poor response (PPR) associated
with T immunophenotype and/or WBC count >100 k/mcL,
patients who underwent a related donor HSCT had an improved
5-year EFS as compared to those treated with chemotherapy
alone, 56.7 ± 5.7 vs. 40.6 ± 3.1%, P = 0.02 (33). Berlin–Frankfurt–
Munster (BFM) group and Associazione Italiana Emotologica
Oncologia Pediatrica (AIEOP) have evaluated patients with
HR-ALL in first remission and compared their OS with chemotherapy alone vs. HSCT. HR criteria in this study included MRDpositive disease at day 78, induction failure, t(4,11) translocation,
and PPR. There was no statistically significant difference in EFS
for patients given HSCT or chemotherapy alone when adjusted
for time waiting to HSCT (34). Thus, studies on the role for HSCT
in ALL have been conflicting but most agree that this procedure
can offer an advantage for at least some high-risk patients (35, 36).
Despite the collaborative efforts of groups worldwide, infants
with ALL have notably inferior outcomes then older children.
Traditionally, infants (<365 days old) were treated on HR protocols with no specificity in regimen; however, this resulted in
suboptimal outcomes, 3-year EFS ~30% (37). Cooperative trial
groups, CCG and POG, demonstrated that intensified systemic
chemotherapy with the addition of intrathecal chemotherapy
led to improved overall survival as compared to previous studies (50 vs. 43%) (38). However, overall relapse rate remained a
major concern, with most relapses occurring within 1 year (39).
Analysis from multiple cooperative study groups identified several prognostic factors that were associated with poor outcomes:
age <6 months, WBC count >50 k/mcl, MLL rearrangement,
and CD10 negativity (38–44). Japanese studies were among the
first to report differences in outcome for patients with germline
MLL as compared to those with MLL-rearranged disease. One
hundred and two infants were enrolled on two Japanese studies,
MLL96/98, with results showing dramatic differences; 22 patients
with germline MLL had 5-year EFS and OS of 96% vs. 80 infants
with MLL rearrangement having a 5-year EFS and OS of 39 and
51%, respectively (42–44). The Interfant Study Group, which
comprises the largest worldwide collaboration devoted to infant
3
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ALL research, also found that infants with germline MLL had
the best outcome, with a 5-year EFS 74% (40). Additionally, for
patients treated on Interfant-99, prednisone-good responders
had more superior 4-year EFS than those with prednisone-poor
response, 56.4 vs. 29.8%, respectively. Nevertheless, the majority
of patients with infant ALL continue to have poor outcomes.
HSCT remains controversial in this subgroup, with some studies
showing no clinical benefit, and in fact some showing worsened
outcome in infants with ALL after transplant (45). Interfant-99
showed no significant difference in EFS comparing patients who
received chemotherapy vs. HSCT (40).
Flt3 kinase is an important oncogene in adult and pediatric
AML and has recently become an area for targeted therapeutics
in infant ALL. Gene-expression studies have shown high levels
of Flt3 in leukemia blasts in infants and children with MLLrearranged leukemia (46). Preclinical data have shown that Flt3
kinase inhibitors have in vitro effects, with most pronounced
response in samples with Flt3 overexpression. The current COG
protocol incorporates the above prognostic factors and classifies
patients into three groups based on MLL rearrangement and age.
In addition to traditional backbone therapy for infant ALL, this
study, AALL0631, is the first trial to incorporate novel targeted
therapy, Flt3 inhibitor- CEP-701 (lestaurtinib) (47, 48). Results
of this study are maturing, however hold promise that small
molecule inhibitors can improve outcomes for infant ALL.

into ETP (11%), near-ETP (those with elevated CD5, 17%), and
not-ETP (72%) based on flow cytometry. In a provocative interim
analysis, contrary to most prior reports, all three groups showed
excellent 5-year EFS and OS that were not statistically significant:
ETP (87, 93%), near-ETP (84, 92%), and not-ETP (87, 92%) using
the treatment approach employed in this protocol (52). However,
they did note that patients with ETP and near-ETP had significantly higher rates of induction failure, 7.8 and 6.7%, respectively,
vs. those with not-ETP 1.1% (P < 0.0001) (52). Additionally, this
study is evaluating whether purine nucleoside analog nelarabine
will improve outcomes for T cell ALL when combined with frontline chemotherapy. Nelarabine is a water-soluble prodrug of
9-B-arabinofuranosylguanine (araG) and inhibits DNA synthesis
by causing accumulation of araG nucleotides in T cells (53, 54).
In a phase II pediatric trial with patients receiving single agent
nelarabine, 106 patients were evaluated and risk-stratified into
four groups based on first or second relapse with >25% blasts
in bone marrow (excluding CNS disease), CNS disease, or those
with <25% relapse in marrow. Response rate was greatest for
patients with first relapse, 55%, with 16 CR and 2 partial remission
(PR) (54). These results hold promise for patients with relapsed
T cell ALL as their overall prognosis is poor with conventional
therapies, and also could be an option for T cell ALL patients as
upfront therapy.

T Cell Leukemia

Acute myeloid leukemia accounts for 20% of newly diagnosed
acute leukemia in pediatrics and, with the exception of acute
promyelocytic leukemia, confers a worse prognosis then ALL
(1). Survival rates for AML have increased dramatically since
1960 with the introduction of more aggressive induction chemotherapy and more intensified regimens. Today, pediatric patients
diagnosed with AML have ~50–60% overall survival (55).
Through the efforts of multiple cooperative studies, numerous
poor prognostic features have been identified; high WBC count,
monosomy 5 or 7, 5q deletion, FLT3-internal tandem duplication
(ITD) with high allelic ratio, and patients with MRD at the end
of the first induction cycle (55–62). In the United Kingdom, the
Medical Research Council (MRC) AML trial 10 demonstrated
that response rate after course 1 of induction was highly predictive of outcome, with those achieving CR having an OS of 53%,
as compared to those with PR, OS 44%, and those with resistant disease, OS 22% (P < 0.0001) (56). Treatment with current
chemotherapy regimens has reached a plateau, as toxicities will
likely preclude further increases in intensity. This emphasizes the
need for more targeted therapies in high-risk pediatric AML.
Flt3 overexpression has been identified as a recurring feature
of multiple leukemias, and, as seen in infant ALL, has created
a lot of interest for targeted therapy in AML. Abnormalities in
the Flt3 gene occur in two ways in AML, point mutations in the
tyrosine kinase domain and ITDs, which are replicates of three
nucleotides that maintain an intact reading frame without disrupting the remainder of the gene (58). A proposed mechanism
of how ITD helps blast cells is by conferring a growth advantage
and self-renewal capacity (59). In a large retrospective review
of AML patients in Japan, 43 subjects were identified as having Flt3-ITD and had significantly worse 5-year DFS of <20%,

Acute Myeloid Leukemia

Historically, patients diagnosed with T cell ALL had worse prognoses than their counterparts with B cell ALL (49). Some reasons
for this include higher WBC count at presentation, increased
induction failure, and increased risk of CNS relapse. With the
implementation of high intensity induction regimens, the EFS
has increased significantly over the last three decades, from 15–20
to 50–85% (49). In a retrospective review done by Dana Farber
Cancer Institute (DCFI), patients with T cell ALL were 8.3 times
more likely to have an induction failure, and were 2.7 times more
likely to have CNS relapse than those patients with B cell ALL.
Despite the significant advances in treatment of T cell ALL, those
who have relapsed disease have dismal outcomes with 3-year EFS
reported at <15% (9, 13, 50). In the COG study AALL01P2, only
2/7 patients with T cell ALL went into a CR2 and no patients with
T cell ALL survived >1 year from relapse (13). In the BFM-ALL
87 relapse study, patients with T cell phenotype had an exceptionally poor outcome, with a 10-year EFS probability estimated at
15 ± 1.0% (P < 0.001) (50). Thus, novel treatment approaches for
relapsed T cell ALL are clearly needed.
The existence of a more immature phenotype of T cell ALL has
been identified in the last decade. Early T cell precursors (ETP)
are thymocytes that have a distinct immunophenotype (CD1a−,
CD8−, CD5dim, +myeloid/stem cell marker) and are thought to
belong to very primitive T cells that have retained multi-lineage
differentiation potential (51). Patients classified as having ETPALL based on immunophenotyping have done significantly
worse than more mature T cell phenotype ALL, one review noting
a 10-year OS for patients with ETP-ALL of 19 vs. 84% for those
with more mature T cell ALL (51). COG study AALL0434 looked
prospectively at patients with T cell ALL and categorized them
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compared to those without Flt3-ITD (5-year DFS of 50%) (57).
Additionally, multiple CCG studies, 2891, 2941, and 2961, have
reviewed pediatric patients and identified that Flt3 ITDs were an
independent poor prognostic factor and that children with an
ITD allelic ratio >0.4 had poor outcomes as compared to those
with Flt3-wild type (60, 61). In the most recent COG study, Flt3
has been added for risk stratification and those with high allelic
ratio of Flt3–ITD will receive more intensive chemotherapy with
a Flt3 inhibitor, and will receive a HSCT in first remission (62).
As discussed above, Flt3 inhibitors are currently being studied
in pediatric phase III trials, in infant ALL (lestaurtinib) and de
novo AML with Flt3–ITD (sorafenib). Continued improvement
in outcomes in high-risk AML will require continued research for
novel therapeutic agents.

regions from heavy and light chains connected by a short linker
sequence to make a singe chain (scFvs) (67, 68). First-generation
CARs incorporated only the CD3-ζ chain of the TCR/CD complex
as the signaling domain but failed to generate potent antitumor
effects. To improve potency, T cell costimulatory domains have
now been included generating second (and third) generation
CARs that incorporate TCR-ζ plus a costimulatory signal such as
the CD28 endodomain. Indeed, a clinical trial in which patients
with refractory non-Hodgkin’s lymphoma (NHL) were simultaneously infused equal amounts of first generation CD-19 targeted
CAR T cells, or second-generation CD-19 CAR T cells clearly
demonstrated that costimulation improved the in vivo expansion
and persistence of CAR-modified T cells when combined with the
costimulatory CD28 domain (69). A costimulatory endodomain
has since been incorporated into most of CAR constructs to
enhance the signaling strength, persistence, and overall potency
of the CAR T cells (70). Multiple costimulatory domains are
currently being investigated, CD28, 4-1BB, OX40, ICOS, and
DAP10; however, no consensus has been reached regarding
which costimulatory domain is superior.

Adoptive Cellular Therapy for Pediatric
Acute Lymphoblastic Leukemia
Immunotherapy has emerged as a promising treatment for
patients with relapsed-refractory acute leukemia over the past
decade. In the simplest sense, the immune system is responsible for surveying the body and eliminating foreign substances
that can cause harm, including the clearance of cells that have
acquired malignant potential. Conceptually, Schreiber et al. has
described cancer immunosurveillance and cancer progression as
a cell editing process proceeding through three sequential phases;
elimination, equilibrium, and escape. If the innate and adaptive
immune systems are unable to rid the body of highly immunogenic transformed cells (elimination phase), the tumor variant
cells become dormant and undergo additional genetic changes
in the face of immune pressure (equilibrium phase) (63). If
immunosurveillance fails to recognize and destroy edited tumor
cells, tumor evasion mechanisms can be acquired such as loss of
tumor-associated antigens (TAAs) or down-regulation of major
histocompatibility complex (MHC) antigens (63, 64). This creates
a state of immune tolerance which in turn creates a microenvironment that allows the tumor to flourish (escape phase) (63).
Genetically engineered T cells using a recombinant T cell receptor (TCR) have been implemented in an attempt to re-direct the
immune system. This recombinant T cell gains high specificity for
antigens expressed on tumor cells (65). These engineered TCRs
showed promise in early clinical trials (64), however had multiple
limitations; namely, human leukocyte antigen (HLA) restriction
that limits patient eligibility, dependency on MHC expression by
tumor cells, and toxicity (65).
More recently, adoptive cellular therapy has now included T
cells genetically modified using CARs that are independent of
MHC restriction. The original concept of CARs was first introduced by Gross et al. in 1989, and significant work has been done
since then to create more sophisticated domains that can enhance
activation, expansion, and survival of modified T cells (66, 67).
CARs are customized receptors that are composed of an extracellular antigen-binding domain targeting antigens expressed on the
malignant cells (such as CD19 expressed on B cell malignancies)
combined with the intracellular signaling domains of the T cell
(64). The antigen-binding domain typically consists of single protein chains derived from monoclonal antibody fragment variable
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Antigen Selection in B ALL
Genetically engineered T cells have become a more realistic option
for those patients with refractory or multiply relapsed acute leukemia for which conventional therapies have failed. Hematologic
malignancies have been a prime example in the development of
antibody-based immunotherapy (including CAR T cells which
use an antibody-derived binding domain) because of cell surface
antigens well known through flow cytometry; many of which
have restricted expression to hematopoietic lineages with potential for regeneration of the non-malignant cells expressing the
same target after completion of therapy. Ideally, an antigen target
is one that has high expression on the malignant cell surface, and
is not detected on normal tissues (or at least limited), therefore
maximizing selectivity and minimizing off-tumor toxicity (71).
In the context of cell therapy for leukemia, CD19 has been the
most targeted antigen thus far with multiple trials centered on
relapsed or refractory acute B cell leukemia using anti-CD19
antibodies. This antigen is solely expressed on B cell lineage,
sparing other normal tissues, and is highly expressed on B ALL.
Blinatumamab is a bispecific T cell engaging antibody (BiTE),
anti-CD19/CD3, that has shown efficacy in adult and pediatric
patients with relapsed or refractory ALL (72, 73). In a phase I/
II pediatric study, 32% of pediatric patients with refractory ALL
entered into a cytologic complete remission. Currently, a multicenter phase II/III trial (AALL1331) is underway to determine
if using blinatumamab in upfront relapsed leukemia therapy
increases leukemia-free survival in pediatric patients.
CD19 CAR therapy has revolutionized immunotherapy
for hematologic malignancies with major success in multiple
pediatric phase I studies (74, 75). In one of the largest pediatric studies to date, 30 patients were included, with 25 patients
<22 years old. The CAR construct used was a second generation
with a 41-BB costimulatory domain. Morphologic complete
remission was induced in 27/30 patients, with 81% of those having MRD-negative disease. The 6-month EFS was 67% and OS
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was 78% (74). Lee et al. conducted a phase 1 study with CD19
second-generation CAR using a CD28 costimulatory domain in
21 patients and had a CR of 67%, with 12 patients (86%) achieving
MRD-negative disease. OS was 56% for patients with a median
of 10 months followup. Of those with MRD-negative disease,
10 of them went on to HSCT and all remained disease free at
10 months post HSCT (75). A novel mechanism of tumor escape
has emerged with CAR and bispecific antibody therapy resulting
in relapses with leukemia that no longer express the targeted
CD19 epitope (74–76). The loss of antigen is a potential hurdle in
the development of immunotherapy, thereby making it imperative to develop strategies to optimize, including the identification
of additional targets.
CD22 is another common B-lineage marker that is expressed
on leukemia and for which immunotherapeutic targeting has
recently been developed. Two different CD22 immunotoxins
have been tested against B ALL in clinical trials. In a phase 1
study, moxetumomab pasudotox (anti-CD22 pseudomonas
exotoxin conjugate) showed activity in pediatric patients who
had refractory disease. Twenty-three patients were enrolled in
this phase 1 study and 7/23 patients either had a PR (with >50%
blast reduction) or a CR (77, 78). Another CD22 immunotoxin
(inotuzomab) has been tested primarily in adults with ALL and
has demonstrated overall response rates of 58% in relapsed and
refractory adult patients with acute lymphocytic leukemia (79).
Recently, a CD22 CAR has been developed and shown to have
comparable activity in murine xenografts when compared to
CD19 CAR (80). A phase I study is underway using a CD22 CAR
in patients with relapsed/refractory acute leukemia.
In order to identify novel antigenic targets and to improve
selectivity for malignancy, flow cytometric and genomic data have
been analyzed. A bioinformatics approach using gene-expression
databases (containing multiple tumor samples annotated often
with additional clinical and laboratory information) compares
expression profiles between normal tissues and tumors of interest and can identify potential targets with a favorable expression
profile. For example, genomic profiling of ALL has demonstrated
recurring abnormalities in the CRLF2 gene resulting in overexpression of the encoded protein TSLPR in approximately 5–10%
of B ALL. Importantly, overexpression of CRLF2 seems to confer
a risk of relapse. As a cell surface protein, this oncogenic protein
can be targeted immunotherapeutically. In fact, a TSLPR CAR
has demonstrated potent activity in preclinical models (81).
The large set of genomic data generated by expression profiling
and next generation sequencing can be further analyzed using
algorithms that “filter” for predicted cell surface expression. This
approach has been applied to a number of pediatric malignancies,
including B cell ALL and T cell ALL (82, 83).
To combat common toxicity seen in CD 19 trials, a more
specific targeted CAR has been created in order to try and minimize B cell aplasia. Exploiting the monoclonality of malignant
B cells, a recent phase I study used clonal restriction to create a
k-light chain CAR that specifically targets k+ leukemia and lymphomas. Ten patients have been treated to date, with three dose
levels assessed. Results of five NHL patients have showed promise
with two patients entering a CR and one other showing partial
response. This preliminary study has shown that CAR therapy
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restricted to k-light chain has been effective in patients with k+
lymphoma with diminished effects on the non-malignant B cell
population (84).

Immunotherapeutic Targets in Pediatric
T Cell ALL
As reported in Orentas et al. 2014, Gene Expression Omnibus
(GEO) data containing over 100 samples of T cell ALL were
analyzed to determine which genes encoding cell surface proteins
were most overexpressed in pediatric T cell leukemia in order to
identify novel antigens that may be amenable to targeted therapy.
One of the top transcripts that was notably overexpressed in T cell
ALL as compared to PBMCs was TALLA (83). TALLA has been
previously described by Seon et al. in the 1980s as a hybridoma
monoclonal antibody that had specific target selectivity for T
cell leukemia. Hara and Seon showed that this hybridoma, when
injected in mice with T cell leukemia, resulted in in vivo suppression of tumor growth without overt toxicity (85, 86). Using geneexpression data combined with known activity of a monoclonal
antibody, TALLA may be an area of future research in relapsed or
refractory T cell ALL but will require validation that this antigen
is expressed on the surface of the majority of primary T cell ALL
samples.
As discussed previously, ETP-ALL has typically been more
difficult to treat, with more induction failure than patients with
more mature T cell ALL. Recently, in preclinical studies, Maude
et al. demonstrated aberrant JAK/STAT pathway in ETP-ALL
patient samples. Patient-derived xenograft models were established and ruxolitinib, a JAK1/2 inhibitor, demonstrated robust
activity as a single agent, with a statistically significant reduction
in peripheral blasts as compared to controls in 5/6 xenograft
models. Continued work is needed in this area to further establish
targets for novel treatments (87).
Mamonkin et al. recently developed a CAR directed at CD5
for T cell ALL that showed promising in vitro and in vivo activity.
They demonstrated that CD5 CAR T cells were cytotoxic to five
different CD5+ T cell ALL and T cell lymphoma lines in vitro,
and had no effect on CD5− lines (88). Additionally, they were
able to show that these CD5 CAR T cells had tumor suppression
capabilities when co-cultured for longer periods of time with
these CD5+ cell lines. They were also able to show in vivo activity
of CD5 CAR T cells against T cell ALL in xenograft models, both
when infused early and late after leukemia injection was given.
Xenografts treated with experimental CD5 CAR T cells had
statistically significant survival advantage as compared to control
groups given CD 19 CAR (88). However, complete eradication
was not seen in these models and leukemia blasts retained CD5
cell surface expression, suggesting lack of persistence of CAR.
One of the major challenges of producing a CAR T cell directed
at an antigen on most naïve T cells is protecting healthy T cells
from destruction by CAR therapy. These authors concluded that
self-killing of T cells was limited; T cells co-cultured with CD5
CAR initially declined in number, however had comparable
sustained expansion when compared to the control CD19 CAR
used (88). These data are promising in light of new antigens being
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discovered specifically for a disease subtype in pediatrics that has
limited options in targeted therapy.

have cytotoxic effects with enhanced CAR persistence (90). This
safety mechanism provided by transient persistence is important
as it could avoid prolonged myelosuppression in AML patients.
Multiple groups have recently reported preclinical activity
against CD123 in AML. Pizzitola et al. recently described activity
with cytokine-induced killer cells (CIK) that had been genetically modified to express CD33-CAR and CD123-CAR. What
they found was that mice treated with CIK with either CD33 or
CD123 bound CAR had significant reduction in tumor burden
than those in the control group. Interestingly, when leukemia
returned, analysis was performed and residual AML cells continued to express CD33/123, thus concluding that these cells did
not develop the resistance mechanisms employed as previously
described in CD19 CAR immunotherapy (92). Also, Tettamanti
et al. recently described CD123 as a potent AML target due to
its high expression on AML cells and AML leukemia stem cells
(AML-LSCs) and low levels of expression on hematopoietic
stem cells. In vitro studies demonstrated CIK with anti-CD33 or
anti-CD123 had equal AML cytotoxic effects; however, CD123CAR had a safer toxicity profile toward progenitor cells (93).
Similarly, Mardiros et al. developed a CD123-CAR that showed
specific activity against primary AML samples, in addition to
in vivo activity in xenograft AML models. This study showed
delayed leukemia relapse in xenografts treated with CAR therapy
vs. mock T cells; however, the treatment group did not have
any long-term survivors (94) Gill et al. recently demonstrated
CD123-CAR activity in primary samples and xenograft models,
and was able to show long-term survivors after treatment with
CD123-CARs. This study differed from the others in that they saw
significant hematopoietic progenitor toxicity with their CD123CAR, recommending usage as a bridge or conditioning regimen
for HSCT (95). Finally, CAR T cells targeting the Lewis Y antigen
and the folate receptor β have also shown activity against AML
(96, 97). Thus, there are multiple potential targets for CAR T cells
in AML. However, it remains to be seen whether clinical activity
will be as good as that seen with CD19 CAR T cells in ALL and
the extent to which toxicity against non-malignant myeloid cells
limit development.

CARS in Pediatric AML
As stated above, pediatric patients with relapsed AML have limited therapeutic options with HSCT providing the only curative
potential. Inducing a remission in order to get to transplant in
these relapsed patients becomes challenging due to chemorefractory disease. CD33 targeting has been an area of investigation in
pediatric AML, as seen with the anti-CD33 monoclonal antibody,
Gemtuzumab ozogamicin (GO). In a pediatric clinical trial, it
appeared that children receiving GO had a statistically significantly improved 3-year EFS, 53 vs. 47% (P = 0.05), however the
overall survival did not differ in the groups, thus it was unclear
if GO had any added benefit (89). Several studies are ongoing
testing the efficacy of CD33-directed CAR therapy. Kenderian
et al. developed four constructs using the scFv region of GO
and tested these targeted agents against AML cell lines, patient
AML samples, and xenografts. The CD33 CARs demonstrated
significant cytotoxicity and cellular degranulation against AML
cell lines, with significant in vitro activity against primary AML
samples as well. Significant reduction in tumor burden and a
survival advantage was seen in mice injected with CD33 CAR
vs. those injected with control T cells (90). Toxicity associated
with this CAR resulted in decrease in myeloid progenitor cells,
which was expected based on CD33 expression (90). Similarly,
O’Hear et al. recently described a novel second-generation CD33
CAR that incorporated 41-BB costimulatory endodomain used
in preclinical models. AML cell lines, xenografts, and primary
pediatric samples were assessed. Specific tumor killing of CD33+
AML cell lines was seen when co-cultured with CD33 CAR, and
these cultures had higher levels of cytokines when compared to
the cell lines co-cultured with control vector transduced T cells.
This same result was seen with primary AML samples, and interestingly, the extent of killing did not correlate with the cell surface
level of expression of CD33 (91). Additionally, xenografts were
established and studied in two ways: (1) to determine if CAR T
cells could prevent the development of AML and (2) to determine
if CAR T cells could treat AML. Mice were injected with AML
and, in the first model, were immediately injected with either
CAR T cells, viral transduced T cells, or saline. Results showed
rapid development of leukemia in the two control groups with
<1% of AML cells detected in those injected with CAR T cells.
Also in established leukemia models, treated as per the three
groups above, CAR T cells resulted in significant reduction in
tumor burden with a statistically significant survival advantage
compared to mice treated with control cells (91). Results of these
preclinical models are promising for creating a CAR construct to
combat relapsed or refractory AML.
In an attempt to overcome the significant hematopoietic
toxicity associated with CD33 targeted therapy, Kenderian et al.
developed a transient CAR using electroporation of T cells with
RNA-modified CD33 CAR. Results of this preclinical model
showed similar eradication of leukemia cells as compared to
lentiviral transduced CD33 CAR, albeit transient in vitro activity.
It was then combined with chemotherapy in vivo and shown to
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The Potential of Combinatorial CAR
Targeting in Pediatric Leukemia
Due to its universal expression on B cell malignancies, CD19
has been an attractive target for CAR-directed therapies. Its
success hinges on the fact that although CD19 is expressed on
normal B cells, the toxicity associated with aplasia of this cellular compartment is tolerable as seen in recent trials (74, 75).
Targeting of other acute hematologic malignancies, AML and
T cell ALL, has been more challenging. Targeting cell surface
molecules universal to these cell types is often detrimental to
normal myeloid and T cell compartments, making it extremely
difficult to identify highly specific CAR targets. In order to
potentiate antitumor activity, and reduce off-tumor toxicity of
normal cellular compartments, combinatorial approaches are
being developed (Figure 1). This proof of concept was introduced by Grada et al. as a tandem CAR using CD19 and HER2
as antigens. This construct was shown to have activity against cell

7

October 2015 | Volume 3 | Article 80

Shalabi et al.

Alternative immunotherapy targets in pediatric leukemia

FIGURE 1 | (A) Second-generation CAR engages the selected target antigen and produces complete T-cell activation through signal 1 provided by the TCR–zeta
and signal 2 provided by costimulatory endodomain 41-BB. (B) Combinatorial CAR T-cell that has two antigens; CAR A provides signal 1 when engaged with Target
A and CAR B provides signal 2 when engaged with Target B. Neither signal can trigger complete T-cell activation individually, sparing healthy tissue that express one
of the antigens.

lines that had single antigens in addition to having synergistic
effect when both antigens were simultaneously encountered
(98). Kloss et al. used a combinatorial approach transducing
T cells with both a CAR that provides suboptimal activation
upon binding of one antigen, and a chimeric costimulatory
receptor that binds a second antigen. Using T cells that were
co-transduced with two prostate antigens, tumors expressing
both antigens were effectively targeted and destroyed while
sparing tumors that expressed one sole antigen (99). Lanitis et al.
identified two potential antigen targets for CAR development for
use in epithelial ovarian cancers using mesothelin (meso) and
a-folate receptor (Fra). Ovarian tumors generally overexpress
both these antigens, while coexpression on normal tissues is
rare. Two separate CARs were created, one with T cell activation
signal 1 (meso-CD3ζ) and the other with costimulatory signal
2 (Fra-CD28), and T cells where then transduced to co-express
both CARs. By using this physical separation barrier, only cells
expressing both antigens would bind and elicit complete T cell
activation needed for antitumor activity. This preclinical model
demonstrated potent anticancer activity in vitro and in vivo
that was superior to first-generation CARs and comparable to
standard second-generation CARs. The major advantage of this
new combinatorial CAR over a standard second-generation
CAR was dissociated signaling of two antigens yielded a better
side effect profile against cross-reactivity with normal healthy
tissues expressing a single antigen (100).
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Combinatorial targeting approaches may be particularly
well suited for pediatric acute leukemia, specifically AML
and T cell ALL that express multiple hematopoietic antigens.
Additionally, varying reports (10–30%) of aberrant lymphoid or
myeloid-associated markers have been demonstrated in pediatric studies of patients with acute leukemia. Conflicting reports
as to the prognostic implications of aberrant phenotypes have
been shown in prospective pediatric studies performed in the
1990s (101–103). Pui et al. found that 16% of pediatric patients
consecutively enrolled on clinical trials had aberrant expression
of myeloid antigens on their ALL blasts, however found that it
did not have an effect on remission or EFS (101). On the other
hand, Wiersma et al. found that 22% of newly diagnosed pediatric
patients expressed myeloid antigens on their leukemia blasts and
in a multivariate analysis, it was found to be the most significant
poor prognostic predictor of relapse in childhood ALL (102).
Although the prognostic significance remains controversial, the
presence of aberrant myeloid antigens is a common occurrence in
childhood ALL (104, 105). Using this to our advantage, one could
construct a combinatorial CAR that has more specificity for these
leukemia blasts and spare normal HSCs.

Other Approaches to Improve Safety
Careful selection of TAAs is of paramount importance due to the
potency of genetically modified T cells and the potential on-target,
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off-tumor toxicity that has been reported. One patient treated for
metastatic colon cancer with Her2/neu CAR T cells died 5 days later
from respiratory failure attributable to cytokine storm potentially
due to low levels of Her2/neu found in lung epithelium (106).
This highlights the importance of assessing for cross-reactivity
on normal cells during the preclinical development of genetically
engineered cells. However, it is likely that it will be challenging
to identify antigens that are exclusively expressed on tumor cells
or that are expressed only by normal cells for which off-tumor
toxicity will be tolerated (such as CD19 on B cells). Indeed,
patients responding to CD19-CAR therapy develop B cell aplasia
noted that can be managed by immunoglobulin infusions. Thus,
approaches to control expansion or persistence of genetically
engineered cells will be important for the clinical development.
For example, inducible caspase 9, an intrinsic apoptotic pathway,
can be incorporated into CAR T cell as a “suicide gene.” Following
an allogeneic transplant, patients were given a donor lymphocyte
infusion of cells modified to express the inducible caspase 9
gene, and had more than 90% of T cells eliminated in 30 min
when given 1 dose of a dimerizing drug (107). This construct is
currently being incorporated into CAR T cells in the context of
clinical trials. Additionally, the use of RNA electroporated CAR
constructs allows for transient expression of CAR in T cells with
retention of potent activity provides a possible strategy to improve
the safety of CAR T cell therapy (90, 108) Finally, using CAR T
cells that express a truncated EGFR can be used as a safety feature
for hematologic CAR targeted therapy. Human epidermal growth
factor receptor is not expressed on cells of the hematopoietic and
lymphopoietic systems; therefore, it will not have an impact on
progenitor cells. Using truncated EGFR-CAR is helpful as it provides a cell surface marker for in vivo tracking of adoptive T cell
therapy. When therapy is completed or toxicities have been noted,
administration of a monoclonal antibody, cetuximab, results in
in vivo cell ablation, thereby employing a safety mechanism that
can ameliorate potential long-term CAR side effects (109).

A relatively common and potentially life-threatening toxicity
seen in CD19 CAR trials is cytokine-release syndrome (CRS), a
systemic, immune-mediated inflammatory response. CRS ranges
in severity from mild (fevers and myalgia) to life threatening
(capillary leak, respiratory failure, hypotension) and is often correlated with high peak levels of IL-6, C-reactive protein, ferritin,
and IL-2 (P < 0.05) (74, 75). It was also noted that higher patient
blast percentages prior to therapy correlated with more severe
CRS and that CRS is often associated with clinical response (74).
For those with more severe CRS, IL-6 blockade and/or glucocorticoids can mediate rapid improvement (74, 75). Thus, there
is interest in developing standard approaches for intervention.
As suggested by Lee et al., creating an algorithm where IL-6
blockade is used as the first line therapy for treatment of severe
CRS can systematically guide therapy for CRS perhaps avoiding
mortality (75).

Conclusion
Exceptional progress has been made over the last two decades
with genetically modified T cells with recent dramatic success
using CAR T cells for pediatric leukemia. With continued
identification of targets, the possibilities of CAR therapy
continue to expand. Careful preclinical and clinical development will be required for the safe and successful incorporation
of genetically modified T cells into treatment paradigms for
cancer. Almost certainly, approaches to manage potential
toxicity to non-malignant tissues due to on-target, off-tumor
reactivity will be required. One strategy is the development
of combinatorial therapy using T cells expressing multiple
CAR constructs thus controlling reactivity based on expression of combinations of targets. Pediatric leukemia may be
particularly amenable to such approaches due to aberrant
expression of cell surface molecules not typically found on
normal hematopoietic cells.
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